EMA Prepares To Deliver Verdict On Bevacizumab In Wet AMD
Opinion Could Be Drug's First OK For Ocular Use
This week could finally see an ophthalmic version of the anticancer drug bevacizumab recommended for use in wet AMD across the EU. Several other new products are also up for a CHMP opinion.
You may also be interested in...
The European Medicines Agency had a busy time at its meeting last week. It gave the green light to 11 products, four of which are for rare diseases including ANCA-associated vasculitis, and to a range of treatments for conditions as diverse as non-small cell lung cancer, smallpox, migraine, COPD, COVID-19 and obesity.
Nearly a year and a half after it was filed for approval, the EU regulator has rejected a mystery injectable product containing the monoclonal antibody bevacizumab for ophthalmic use.
The European Medicines Agency is expected to make recommendations on EU marketing authorization for 10 new medicines at its monthly meeting this week. They include products for non-small cell lung cancer, COVID-19, kidney disease, smallpox and migraine.